Analysis of Differential Resistance Emergence Risk for Differential Treatment App
Analysis of Differential Resistance Emergence Risk for Differential Treatment App
批准号:
7685982
负责人:
RYAN M ZURAKOWSKI
金额:
$20.48万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-06-05 至 2011-05-31
关键词:
AdherenceAlgorithmsAntiviral AgentsAntiviral TherapyCD4 Positive T LymphocytesCell CountCessation of lifeClinicalClinical TrialsDataDevelopmentDisease MarkerEvolutionExperimental DesignsFailureFutureGenerationsGeneticGoalsHIVImmunologic Deficiency SyndromesIncidenceInfectionInterruptionKnowledgeLaboratoriesLeadLeftLife Cycle StagesLife ExpectancyMapsMediatingMethodsModelingMulti-Drug ResistanceMutationOpportunistic InfectionsPatientsPatternPharmaceutical PreparationsPopulationPredispositionPreparationPrincipal InvestigatorProbabilityQuality of lifeRNA-Directed DNA PolymeraseRecommendationRecording of previous eventsResearchResearch Project GrantsResistanceResistance developmentRetroviridaeRiskSamplingScheduleStatistical ModelsTarget PopulationsTechniquesTimeTreatment FailureTreatment ProtocolsVariantViralViral Load resultVirusWorkbasedrug resistant virusimprovedmathematical modelpredictive modelingprogramspublic health relevanceresearch studyresistant strainsuccessvirus genetics
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): This project will develop model-based approaches to therapy switching for HIV which minimize the risk of subsequent treatment failures by simultaneously considering the contributions of the viral and proviral genetic makeup and the total viral load to this risk. Using components of previously failed antiviral regimens, the patient's viral load will be "pre-conditioned" for the new antiviral regimen, to maximize its possibility of success. This approach differs from the previous approaches in several important ways. It focuses on therapy switches in patients who have not yet developed multi-drug resistant virus, for whom potentially successful antiviral regimens still exist. It incorporates into its calculation of risk not only the known incidences of cross-resistance between antiviral drugs, but also the knowledge of genetic distance between dominant resistant strains, based on the patient's history of antiviral use. These approaches to treatment will be based on mathematical models of HIV quasispecies dynamics and the competition between various viral strains during different treatment application schedules, as well as mathematical models of resistance emergence. These models will be used to develop laboratory and clinical experiments as future work to implement these techniques. The model- based algorithmic therapy-switching schedules should significantly reduce the risk of failure of subsequent antiviral therapy by reducing the risk of resistant virus pre-existing its introduction. PUBLIC HEALTH RELEVANCE: If successful, this research will provide a method to reduce the incidence of HIV treatment failure due to resistant virus. This has the potential to extend the life expectancy of thousands of people infected with the HIV virus, and to improve their quality of life. Application of this method may also reduce the overall incidence of multi-drug resistant virus in the population.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
HIV 2-LTR Dynamics and Cryptic Viremia
-
批准号:8732302
-
项目类别:
-
资助金额:$21.48万
-
财政年份:2014
-
负责人:RYAN M ZURAKOWSKI
-
依托单位:
Analysis of Differential Resistance Emergence Risk for Differential Treatment App
-
批准号:7860447
-
项目类别:
-
资助金额:$19.13万
-
财政年份:2009
-
负责人:RYAN M ZURAKOWSKI
-
依托单位:
海外基金